Dr. Matthew Christopher Weed, MD

Dr. Weed practices at Surgery Center Spokane Eye Clinic in Spokane, Washington.

Dr. Weed's NPI, 1780995993, was assigned on June 23, 2010. Dr. Weed graduated from University of California, San Diego School of Medicine in 2010. Dr. Weed holds Washington license MD60625861.

Dr. Weed's primary practice is Surgery Center Spokane Eye Clinic, at 9651 N Nevada St, Spokane, WA 99218 in Spokane County. The practice phone is (509) 456-0107.

Dr. Weed's primary practice is Surgery Center Spokane Eye Clinic in Spokane, Washington. Dr. Weed is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Weed to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weed practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Weed's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Weed's licenses on file in 2 states: Washington and Iowa.

CMS data shows 182 Medicare services from Dr. Weed across 5 procedure codes in 2024, for 102 Medicare patients. Medicare paid $11,755 for them. Every service was in an office.

CMS counts 102 Medicare patients who saw Dr. Weed in 2024. The largest group is 75 to 84, with 45 patients. 75% of them have high blood pressure, and 67% have high cholesterol. Their average risk score is 1.31, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Weed's median patient age at 8, with 44% women.

In 2024, Dr. Weed wrote 54 Medicare Part D claims for 24 patients. 78% of them were for generic drugs. CMS names the drug for 18 of them, across 1 drug with 11 or more claims each, at $248 in total drug cost. In 2023, CMS named 20 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Weed for performance year 2024, reported as part of a group. Dr. Weed accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Weed, published from 2019 to 2024. Dr. Weed's most frequent co-authors are Melinda Youeen-Wu Chang, MD, Vicki M. Chen, MD and Daniel Youngwhan Cho, MD, PhD.

CMS Open Payments shows 8 general payments to Dr. Weed from 2 drug and device companies from 2017 to 2022. Ownership or investment make up the largest share, 94% of the total. US Retina LLC paid the most, $667.

Dr. Weed graduated from University of California, San Diego School of Medicine in 2010.